GW & Wade’s Rein Therapeutics RNTX Stock Holding History

GW & Wade’s Portfolio RNTX Stock Details RNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-5,050	Closed	-$103K	–	404
2021 Q3	$103K	Hold	5,050	–	–	﹤0.01%	376
2021 Q2	$126K	Hold	5,050	–	–	0.01%	377
2021 Q1	$144K	Buy	+5,050	New	+$173K	0.01%	349

Other funds holding RNTX

AIM

Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

KCK Ltd Hamilton, Bermuda $15.1M AUM 30.14% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

GW & Wade's RNTX Position: Q4 2021 in Review

GW & Wade sold out of Rein Therapeutics (RNTX) in Q4 2021, closing a stake of 5,050 shares — an estimated $103K sold.

GW & Wade first reported a position in RNTX in Q1 2021 and held it in 3 quarters. The position peaked at $144K in Q1 2021. 43 funds tracked by Wall St. Rank hold RNTX as of Q4 2021.

GW & Wade reported no remaining Rein Therapeutics position as of Q4 2021 after selling out during the quarter.
GW & Wade sold 5,050 Rein Therapeutics shares in Q4 2021, an estimated $103K.
GW & Wade first reported a position in Rein Therapeutics in Q1 2021 and held it in 3 quarters.
GW & Wade's Rein Therapeutics position peaked at $144K in Q1 2021.
43 funds tracked by Wall St. Rank held Rein Therapeutics as of Q4 2021.

Based on GW & Wade's 13F filing for Q4 2021, filed 9 Feb 2022.